Key result
Qiliqiangxin treatment significantly reduced infarct size, decreased mortality at 7 days, and improved cardiac function in a mouse model of cardiac ischemia-reperfusion injury.
Why the study?
Does Qiliqiangxin protect against cardiac ischemia-reperfusion injury in a mouse model?
Population
Mouse model of cardiac ischemia-reperfusion established by ligation of the left anterior descending coronary…
Comparison
Qiliqiangxin administered for three days before… vs Control group
Design
Preclinical
Follow-up
7 days
Authors
Loading...
May support further preclinical study of Qiliqiangxin; leaves open translation to human ischemia-reperfusion injury.
Does Qiliqiangxin protect against cardiac ischemia-reperfusion injury in a mouse model?
Qiliqiangxin protects against cardiac ischemia-reperfusion injury and attenuates adverse remodeling in a mouse model, likely via mTOR pathway activation.
Zhou et al. (2015) studied Cardiac ischemia-reperfusion (I/R) injury. Qiliqiangxin (QL) vs. Control group was evaluated on Infarct size, mortality, and cardiac function. Qiliqiangxin treatment significantly reduced infarct size, decreased mortality at 7 days, and improved cardiac function in a mouse model of cardiac ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: